BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Gilead Sciences, Inc. 

333 Lakeside Drive

Foster City  California  94404  U.S.A.
Phone: 800-GILEAD-5 or 650-574-3000 Fax: 650-522-5800


SEARCH JOBS




Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need.The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.


 Key Statistics


Email:
Ownership:

Web Site: Gilead Sciences, Inc.
Employees: 4,000
Symbol: GILD
 



Industry
Biotechnology






 Company News
Analyst: Gilead Sciences, Inc. (GILD) Still A Buy After Cancer Drug Fail 9/17/2014 5:49:21 PM
Hetero Enters License Agreement With Gilead Sciences, Inc. (GILD), U.S.A. To Produce Generic Sofosbuvir For Treatment Of Chronic Hepatitis C 9/17/2014 9:41:26 AM
Gilead Sciences, Inc. (GILD)'s Experimental Drug Simtuzumab Fails Mid-Stage Study 9/17/2014 6:00:11 AM
Mylan Inc. (MYL) Signs Agreement With Gilead Sciences, Inc. (GILD) To Accelerate Access To Hepatitis C Treatments, SovaldiĀ® (Sofosbuvir) And Single Tablet Regimen Of Ledipasvir/Sofosbuvir, in Developing Countries 9/15/2014 8:39:58 AM
Retrophin, Inc. (RTRX), Gilead Sciences, Inc. (GILD), And Our Healthcare Values 9/15/2014 6:47:12 AM
Gilead Sciences, Inc. (GILD) Says Indian Firms May Sell Generics of Hep C Drug Sovaldi 9/15/2014 6:05:24 AM
Gilead Sciences, Inc. (GILD) Release: First-Line Combination Of Ambrisentan And Tadalafil Reduces Risk Of Clinical Failure Compared To Monotherapy In Pulmonary Arterial Hypertension Outcomes Study 9/8/2014 10:52:13 AM
Gilead Sciences, Inc. (GILD) Close To Inking Deal That Would Bring Low-Cost Versions Of $84,000 Solvadi Drug To Poor Countries 9/5/2014 6:37:43 AM
Gilead Sciences, Inc. (GILD) To Present At Two Upcoming Investor Conferences In September 9/4/2014 12:38:18 PM
Gilead Sciences, Inc. (GILD), "The New Genentech (RHHBY)," Remaps Massive Foster City Campus 8/29/2014 6:44:11 AM
12345678910...